Recurrent point mutations in the kinetochore gene KNSTRN in cutaneous squamous cell carcinoma

Article metrics

Subjects

Abstract

Here we report the discovery of recurrent mutations concentrated at an ultraviolet signature hotspot in KNSTRN, which encodes a kinetochore protein, in 19% of cutaneous squamous cell carcinomas (SCCs). Cancer-associated KNSTRN mutations, most notably those encoding p.Ser24Phe, disrupt chromatid cohesion in normal cells, occur in SCC precursors, correlate with increased aneuploidy in primary tumors and enhance tumorigenesis in vivo. These findings suggest a role for KNSTRN mutagenesis in SCC development.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Figure 1: Recurrent mutations in KNSTRN encoding p.Ser24Phe in cutaneous SCC.
Figure 2: Ser24Phe kinastrin promotes aneuploidy and enhances tumorigenesis in vivo.

Accession codes

Accessions

NCBI Reference Sequence

References

  1. 1

    Lomas, A., Leonardi-Bee, J. & Bath-Hextall, F. Br. J. Dermatol. 166, 1069–1080 (2012).

  2. 2

    Durinck, S. et al. Cancer Discov. 1, 137–143 (2011).

  3. 3

    Fang, L., Seki, A. & Fang, G. Cell Cycle 8, 2819–2827 (2009).

  4. 4

    Vogelstein, B. et al. Science 339, 1546–1558 (2013).

  5. 5

    Dunsch, A.K., Linnane, E., Barr, F.A. & Gruneberg, U. J. Cell Biol. 192, 959–968 (2011).

  6. 6

    Davoli, T. et al. Cell 155, 948–962 (2013).

  7. 7

    Zack, T.I. et al. Nat. Genet. 45, 1134–1140 (2013).

  8. 8

    Biesterfeld, S., Pennings, K., Grussendorf-Conen, E.I. & Böcking, A. Br. J. Dermatol. 133, 557–560 (1995).

  9. 9

    Ziegler, A. et al. Nature 372, 773–776 (1994).

  10. 10

    Ziegler, A. et al. Proc. Natl. Acad. Sci. USA 90, 4216–4220 (1993).

  11. 11

    Kretz, M. et al. Genes Dev. 26, 338–343 (2012).

  12. 12

    Liu, X., Jian, X. & Boerwinkle, E. Hum. Mutat. 34, E2393–E2402 (2013).

  13. 13

    Li, H. & Durbin, R. Bioinformatics 25, 1754–1760 (2009).

  14. 14

    McKenna, A. et al. Genome Res. 20, 1297–1303 (2010).

  15. 15

    Koboldt, D.C. et al. Bioinformatics 25, 2283–2285 (2009).

  16. 16

    Deng, X. BMC Bioinformatics 12, 267 (2011).

  17. 17

    DePristo, M.A. et al. Nat. Genet. 43, 491–498 (2011).

  18. 18

    Ng, S.B. et al. Nature 461, 272–276 (2009).

Download references

Acknowledgements

We thank J.G. Rheinwald (Dana-Farber/Harvard Cancer Center) for his generous gift of SCC cell lines. We thank A.E. Oro, H.Y. Chang, M. Diehn, M.P. Scott, S.E. Artandi, G.R. Crabtree and T. Waldman as well as A. Zehnder, X. Bao, B.K. Sun, R.J. Flockhart and V. Lopez-Pajares for presubmission review and helpful comments. This work was supported by the US Veterans Affairs Office of Research and Development and by US National Institutes of Health/National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIH/NIAMS) grant AR43799 to P.A.K. C.S.L. is the recipient of career award K08 AR064732 from the NIH/NIAMS. A.S. is supported by NIH/National Institute of General Medical Science (NIGMS) grant GM074728 and American Cancer Society grant 120161-RSG. W.L.J. is the recipient of National Science Foundation (NSF) graduate research fellowship grant DGE-114747.

Author information

C.S.L. designed and executed experiments, analyzed data and wrote the manuscript. A.M., A.B., C.J.A., C.B.N., W.L.J., E.J.R., A.U. and Z.S. helped execute experiments, analyzed data and contributed to the design of experimentation. A.S. helped design experiments and analyzed data. J.K. and S.Z.A. performed tumor tissue acquisition and analysis. P.A.K. designed experiments, analyzed data and wrote the manuscript.

Correspondence to Paul A Khavari.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Integrated supplementary information

Supplementary Figure 1 Comparison of mutation frequency in TP53, CDKN2A and HRAS between data in the COSMIC database and this study.

Supplementary Figure 2 Expression of kinastrin in human skin and SCCs.

(a) Kinastrin is expressed in a broad variety of tissues. Kinastrin expression was extracted from the NextBio Body Atlas application (PLoS One 5, e13066, 2010). The dotted line indicates median expression. (b) Kinastrin expression in progenitor human primary keratinocytes11. The average FPKM of all expressed genes (FPKM > 1.5) in this population is shown for reference. (c) Kinastrin is expressed in normal skin and SCCs. Kinastrin expression was assayed in 76 cases of cutaneous SCC and 5 normal skin samples; representative images are shown. Scale bar, 25 μm.

Supplementary Figure 3 Somatic KNSTRN p.Ser24Phe mutations in SCC.

KNSTRN p.Ser24Phe mutations were confirmed by Sanger sequencing. Sequence chromatograms from a representative SCC and normal skin (NL) sample from the same individual are shown.

Supplementary Figure 4 KNSTRN mutations in SCC compared to other cancer types.

(a) KNSTRN mutation frequency by cancer type (Cancer Discov. 2, 401–404, 2012). (b) Distribution of mutations in the kinastrin coding sequence (Cancer Discov. 2, 401–404, 2012). The labeled mutations disrupt sister chromatid cohesion in normal cells. SXLP, SXLP motif; CC, coiled-coil region.

Supplementary Figure 5 Enforced expression of kinastrin p.Ser24Phe is stable in normal cells.

Western blot analysis of early-passage primary human keratinocytes following transduction with the three kinastrin isoforms. Endogenous kinastrin expression is shown in lane 1; only isoform 3 is present. Lanes 6 and 7 show the enforced protein expression used to assess sister chromatid cohesion and DNA content. Numbers indicate molecular mass in kilodaltons.

Supplementary Figure 6 Kinastrin p.Ser24Phe disrupts chromatid cohesion in SCC-13 cells.

(a) Western blot analysis of SCC-13 cells following transduction with N-terminally tagged (Flag-HA-(poly)His) kinastrin p.Ser24Phe versus wild-type kinastrin. The lower- and higher-molecular-weight bands represent endogenous and enforced kinastrin expression, respectively. (b) Quantification of unpaired chromatids. *P = 0.013, **P = 0.008; ns, not significant.

Supplementary Figure 7 Cancer-associated KNSTRN mutations disrupt chromatid cohesion in normal cells.

(a) Western blot analysis of early-passage primary human keratinocytes following transduction with KNSTRN p.Arg11Lys, p.Pro26Ser, p.Pro28Ser and p.Ala40Glu versus wild-type kinastrin. (b) Quantification of unpaired chromatids. *P = 0.05, **P < 0.03.

Supplementary Figure 8 Kinastrin p.Ser28Phe enhances aneuploidy in normal cells.

Early-passage, pooled primary human foreskin keratinocytes were transduced with dominant-negative p53 and LacZ (CTR), wild-type kinastrin (WT) or kinastrin p.Ser28Phe (S24F). Cells were grown in paclitaxel for 68 h to induce aneuploidy. (a) Percentage of primary human keratinocytes with DNA content >4N. Data shown represents the mean ± s.d. for biological duplicates with technical triplicates. *P = 0.0014, **P = 0.0004; ns, not significant. (b) Representative plots of cell cycle analysis are shown.

Supplementary Figure 9 Kinastrin p.Ser28Phe does not affect cell growth or cell cycle kinetics.

Early-passage primary human keratinocytes were transduced with LacZ (CTR), wild-type kinastrin (WT) or kinastrin p.Ser28Phe (S24F). (a) Equal numbers of cells were seeded in duplicate, and cell growth assays were performed in technical triplicates at each of the time points shown. (b) Asynchronously proliferating cells were stained with propidium iodide and assayed by flow cytometry in technical duplicates.

Supplementary information

Supplementary Text and Figures

Supplementary Figures 1–9 (PDF 2225 kb)

Supplementary Tables 1–7

Supplementary Tables 1–7 (XLS 2080 kb)

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Further reading